Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.ents. Correlates with Alzheimer disease
Several selective antagonists for adenosine A2A receptors (A2AR) are currently under evaluation in clinical trials (phases I to III) to treat Parkinson's disease, and they will probably soon reach the market. The usefulness of these antagonists has been deduced from studies demonstrating functi...
| Main Authors: | , , , , , |
|---|---|
| Format: | info:eu-repo/semantics/article |
| Language: | eng |
| Published: |
Pergamon Elsevier Science LTD
2012
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10171/22827 |